Background: For patients recovering from severe acute illness, admission to a long-term acute care hospital (LTAC) is an increasingly common alternative to continued management in an intensive care unit (ICU).
L ong-term acute care hospitals (LTACs) provide complex inpatient services for patients in the recovery phase of severe acute illness. 1 Defined by the Centers for Medicare and Medicaid as acute care hospitals with average lengths of stay exceeding 25 days, LTACs are among the fastest growing segments of acute care in the United States. Before the 2007 moratorium on the certification of new LTACs, the number of LTACs in the United States grew at a rate of 8.8% per year, with over 400 LTACs currently in operation. 2 LTAC spending has grown at a comparable rate-Medicare reimbursement for LTACs was $4.6 billion in 2008, up from $398 million in 1993. 3 Among other roles, LTACs act as specialized centers for patients with chronic critical illness and those receiving prolonged mechanical ventilation. 4 These patients comprise a minority of intensive care unit (ICU) patients, however, account for a disproportionate amount of resource use, with frequent care transitions and poor long-term outcomes. [5] [6] [7] [8] Studies show that patients with chronic critical illness transferred to LTACs have poor survival. 9 Yet, relatively little is known about how these outcomes differ from patients who remain in ICUs. 10, 11 LTACs might improve outcomes by offering specialized rehabilitation services and dedicated respiratory care, 12, 13 or might worsen outcomes by providing less intense nurse and physician staffing 14, 15 and by disrupting the episode of acute care. 16 To address this issue, we examined the survival and health care costs of fee-for-service Medicare beneficiaries with chronic critical illness transferred to LTACs compared with patients who remain in an acute care ICU.
METHODS

Design Overview
We performed a retrospective cohort study of Medicare beneficiaries with chronic critical illness, comparing survival and health care utilization between patients transferred to an LTAC and patients who remained in an acute care ICU. We used an instrumental variable approach to account for possible unmeasured differences between patient groups. Instrumental variables are a well-developed econometric technique for addressing selection bias and unmeasured confounding in observational studies. 17 
Setting and Participants
We used the Medicare Provider Analysis and Review (MedPAR) Files from 2002 to 2006, which contains demographic and administrative data on all fee-for-service Medicare beneficiaries. MedPAR is the only national source of data on LTAC admissions, and Medicare is the primary payer for approximately 75% of LTAC discharges. 1 We linked MedPAR to patient-level survival data from the Medicare Denominator File, ZIP-code-level population data from the United States census, and year-specific hospital characteristics from the Centers for Medicare and Medicaid Healthcare Cost Report Information System (HCRIS).
We included patients hospitalized in traditional acute care hospitals with chronic critical illness. We defined chronic critical illness as both having received mechanical ventilation, identified using International Classification of Diseases, version 9.0-Clinical Modification (ICD-9-CM) procedures codes 96.7X, and having been admitted to an ICU for at least 14 days, identified using ICU-specific revenue codes. This previously validated definition has 87.6% sensitivity and 88.5% specificity for prolonged mechanical ventilation and identifies a subset of ICU patients with high costs and poor outcomes. 18 We excluded patients 66 years and younger to ensure a homogenous elderly population, and patients with <1 year of Medicare enrollment at the time of eligibility to enable complete comorbidity assessments. We also excluded patients admitted to hospitals in Alaska and Hawaii, as the unique geography of these states limits access to LTACs.
Variables
The primary exposure variable was transfer from an acute care hospital to an LTAC. We defined LTACs using hospital identifiers in MedPAR and HCRIS, as previously described. 2 We considered a patient to have been transferred to an LTAC if they were discharged from an acute care hospital on day n and admitted to an LTAC on day n or n+1. 19 This method is superior to using the discharge location field in MedPAR, which may be inaccurate. 20 The primary outcome variable was survival within 1 year of admission to the acute care hospital, defined using death dates from the Medicare Denominator File. Secondary outcome variables were costs from the hospital perspective and spending from Medicare's perspective. We evaluated 3 types of costs and spending: costs and spending for the entire initial acute care episode including the acute care and LTAC hospitalizations; costs and spending for postacute care hospitalizations include skilled nursing facility (SNF) admissions, rehabilitation hospital admissions, subsequent short-stay hospital admissions, and subsequent LTAC admissions after the first episode of acute care but within 180 days of the initial hospitalization; and total 180-day hospitalization-related costs and spending including both the initial acute care episode and the postacute care periods. We chose a 180-day cut off these health care utilization measures to increase the chance that the utilization was related to the initial episode of critical illness. We did not analyze outpatient or home health costs to maximize the likelihood that the costs were attributable to the events of the initial acute care episode. Although we truncated our assessments of costs, other variables such as length of stay were not truncated.
Costs were determined by multiplying departmentspecific charges in MedPAR by department-specific cost-tocharge ratios in HCRIS. 21 Medicare spending was calculated directly from MedPAR. All costs were adjusted for inflation using the consumer price index and are presented in 2006 US dollars. To understand the mechanism of any observed differences in costs and spending, we also evaluated the number of hospitalizations within 180 days after the initial episode of acute care, including readmissions to acute care hospitals and admissions to SNFs.
Covariates in the analysis included age, sex, race (categorized as black, white, and other), socioeconomic status as measured by the median income of each patient's ZIP code of residence, admission source, primary diagnosis (categorized using the Agency for Healthcare Research and Quality's Healthcare Costs and Utilization Project Clinical Classification Software), and comorbidities defined in the manner of Elixhauser using ICD-9-CM codes for the initial hospitalization and all hospitalizations within the previous 1 year. 22 We also included hospital-level covariates including ownership (categorized as for-profit, nonprofit, and government) and academic status (defined using resident-tobed ratios), derived from the HCRIS files.
Statistical Analysis
We described hospital and patient characteristics using standard summary statistics. To better understand the role of LTAC availability in the selection of patients for transfer, we examined patient characteristics separately for Dartmouth Atlas hospital referral regions (HRRs) that contained an LTAC and HRRs that did not contain an LTAC. For these analyses we judged differences using clinical rather than statistical significance, as because of our large sample size all comparisons would likely be statistically significant.
We examined the relationship between LTAC transfer and our outcomes of interest by fitting a series of regression models. For survival, we used proportional hazards regression in which we treated transfer to LTAC as a time-varying covariate to avoid immortal time bias-a form of bias that occurs when a patient cannot meet the outcome before a timevarying exposure. 23 In this case, patients who are transferred to an LTAC cannot die before transfer. For costs and payments we used linear regression in which the dependent variables were untransformed costs and payments. 24 For hospital readmissions and SNF admissions, we used Poisson regression in which the dependent variables were a count of readmissions or admissions. We treated readmissions and SNF admissions as counts in which each patient could experience multiple events, rather than as a binary covariate in which each patient could experience only 1 event, to more fully capture any downstream effects of LTACs on outcome.
We performed each analysis in a sequential 3-step process. First, we estimated the effect of LTAC transfer with no other covariates in the model. Next, we estimated the effect of LTAC transfer in multivariate regression model controlling for patient and hospital characteristics, as defined above. Finally, we used an instrumental variable approach to attempt to account for the selection bias and unmeasured confounding inherent in our observational study design.
Valid instruments are causally related to the exposure of interest but unrelated to the outcome of interest except through the pathway of the exposure itself. We used 2 instruments: the distance from the admitting hospital to the nearest LTAC obtained as the linear arc distance through geocoding software (ArcGIS, ESRI, Redlands, CA) and the number of LTACs in the admitting hospitals' Dartmouth Atlas HRR, which we created using year-specific ZIP-codeto-HRR crosswalks available from the Dartmouth Atlas. These instruments are based on a conceptual model of LTAC transfer in which clinicians and LTACs determine transfers based on proximity and availability. This model is more consistent with LTAC admission than traditional models of patient choice, as patients and their surrogates are typically unaware of LTACs as a treatment option.
We explored the validity of our instruments by examining the multivariate relationship between the instruments and our exposure, the multivariate relationship between the instruments and our outcomes, and the relationship between our instruments and other factors that might be acting as proxies for hospital quality. These analyses are shown in the supplemental digital content and suggest that our instruments are sufficiently correlated with our exposure and uncorrelated with outcome to act as valid instruments (see Supplemental Digital Content, Methods and Tables 1-3, http://links.lww. com/MLR/A322).
We implemented our instrumental variable approach using either 2-stage prediction inclusion or 2-stage residual inclusion. 25 In the first-stage models, we regressed transfer to an LTAC on our instruments and the complete set of covariates. In the second-stage models, we regressed our outcome on either the predicted value of the dependent variable from the first-stage model and the complete set of covariates (in the case of prediction inclusion); or the actual exposure, the complete set of covariates, and the residuals from the first-stage models (in the case of residual inclusion).
For the survival models, the first-stage model used linear regression predicting time to LTAC transfer and the second-stage model used proportional hazards regression on predicted time to transfer. In these models, patients who died before their predicted LTAC time were considered to have not been transferred to an LTAC-this approach avoids biasing the results by attributing mortal time to the LTAC and avoids the exposure postdating the outcome. For the cost and spending models, the first-stage model used logistic regression predicting LTAC transfer and the second-stage model used linear regression on actual LTAC transfer and the residuals from the first-stage model. For the hospital readmission and SNF admission models, the first-stage model used logistic regression predicting LTAC transfer and the second-stage model used Poisson regression on actual LTAC transfer and the residuals from the first-stage model. In all the models we accounted for hospital-level clustering with generalized estimating equations, specifying robust Huber-White confidence intervals and an exchangeable correlation matrix. 26 We also conducted a series of sensitivity analyses to examine the robustness of our analyses to model assumptions. In these analyses, we shortened the ICU length of stay required to meet our definition of chronic critical illness to account for patients transferred to LTACs before meeting the criteria. We also excluded hospitals in which an LTAC is colocated with the hospital and hospitals in HRRs without LTACs, as the decision to transfer a patient to an LTAC may be fundamentally different in these hospitals than others. Finally, we performed a sensitivity analysis on costs and payments in which we modeled these variables using the gamma distribution rather than the normal distribution. 27 Data management and analysis was performed in SAS 9.2 (SAS Institute, Cary, NC). A P-value of r0.05 was considered significant. All work was reviewed and approved by the University of Pennsylvania and University of Pittsburgh Institutional Review Boards.
RESULTS
There were 9,093,159 hospitalizations during the study period. We excluded 434,650 patients less than or equal to 66 years of age, 85,982 patients from hospitals in Alaska and Hawaii, 8,328,171 patients not meeting our definition of chronic critical illness, and 9557 hospitalizations that occurred subsequent to the first. After exclusions, a total of 234,799 patients met the eligibility criteria. Of these, 48,416 (20.6%) were transferred to an LTAC. In HRRs with at least 1 LTAC, 43,540 of 167,596 patients were transferred (26.0%), whereas in HRRs with no LTACs, 4876 of 66,843 patients were transferred (7.3%). Eligible patients came from 2609 hospitals (Table 1) . Hospitals were diverse in academic status, the number of patients with chronic critical illness, the number of LTACs and LTAC beds in the HRR, and the percent of patients transferred to an LTAC.
A total of 356 LTACs received patients in transfer. Of these, 173 (50%) were colocated in an acute care hospital and 173 (50%) were free-standing LTACs; 248 (71.7%) were for-profit facilities, with the rest being nonprofit (78, 22.5%) and government owned (20, 5.8%).
Patient characteristics and unadjusted outcomes are shown in Table 2 . Measured demographic and clinical characteristics were similar between patients transferred to LTACs and patients who remained in ICUs. Patients transferred to LTACs experienced slightly shorter lengths of stay in the initial hospital but longer total length of stay when LTAC length of stay was included. Unadjusted hospital readmission, SNF admission, and 1-year mortality were similar across patient groups.
Unadjusted and adjusted survival estimates are shown in Table 3 . In the base analysis, the unadjusted hazard ratio for transfer to an LTAC was 1.21 (95% CI, 1.19 to 1.22, P < 0.001). This estimate did not appreciably change after adjusting for patient-level covariates. In our instrumental variable analysis, however, there was no association with LTAC transfer and survival (adjusted hazard ratio = 0.99, 95% CI, 0.96 to 1.01, P = 0.27). In our sensitivity analysis, the results did not change when we excluded hospitals with colocated LTACs or in HRRs without LTACs. LTACs appeared moderately beneficial when our definition of chronic critical illness was broadened to include patients with shorter ICU lengths of stay.
In analyses of our secondary outcomes, adjusting for patient characteristics and utilizing our instrumental variables demonstrated that transfer to an LTAC was associated with lower postacute care costs ($9463 lower; 95% CI, $6465 to $12,450), lower total costs ($13,442 lower; 95% CI, $223 to $26,662), but higher Medicare payments ($15,592 higher; 95% CI, $6343 to $24,842) compared with patients who were not transferred to an LTAC (Table 4 ). Reductions in costs were primarily because of reductions in postacute care hospitalizations. The cost and payment results did not substantively change when we modeled costs and payments using the gamma distribution instead of the normal distribution (see Supplemental Digital Content, Table 4 , http:// links.lww.com/MLR/A323).
DISCUSSION
In our national study of elderly Medicare beneficiaries, patients with chronic critical illness transferred to LTACs experienced similar 1-year survival and lower 180-day hospitalization-related costs compared with patients who remained in acute care ICUs. These results were robust to varying assumptions about patients and hospitals eligible for the analysis, with some sensitivity analyses suggesting that LTACs might improve survival for patients when the population of eligible patients is expanded to include those earlier in their ICU course. Our study provides important conceptual support both for the LTAC model in chronic critical illness and for the utility of comparative effectiveness research in evaluating the organization of care for the critically ill.
Before performing our analyses, we had several hypotheses as to why LTACs might either improve or worsen survival. LTACs might improve survival by providing greater clinical experience in the care of patients with prolonged mechanical ventilation 28 or by providing specialized weaning and rehabilitation services for the chronically critically ill. 7 At the same time LTACs might worsen survival by offering less-intense nurse and physician staffing, which are known to be strongly associated with outcomes. 14, 15 Our analysis demonstrates that these effects either do not strongly affect survival or counteract in way that makes overall survival similar.
We also show that hospitalization-related costs are lower for patients transferred to LTACs, primarily driven by a reduction in SNF admissions. Postacute care utilization is an increasingly important driver of health care costs. 29 Our findings suggest that more intense acute care early in the form of LTAC admission may ultimately prevent postacute care use later in the form of SNF admissions, at least in the subset of hospitalized patients with chronic critical illness. Importantly, despite finding reduced costs for these patients, we found that LTAC use increased Medicare payments. These results suggest a potential disconnect between payments and cost for Medicare patients transferred to LTACs. Ideally, services that are cost-saving from a societal perspective should also save money for health care payers, so long as those services are appropriately incentivized. However, were hospital care to be overvalued by payers, hospitalizations may be reimbursed out of proportion to their value. Innovative payment strategies such as bundled payments for episodes of care 30 and accountable care organizations 31 may make LTACs more attractive for Medicare in the future.
The results of our instrumental analyses differ markedly from the results of the other analyses. In the multivariate model adjusting for observed confounders, admission to an LTAC was associated with shorter survival and higher costs, whereas in the instrumental variable analyses admission to an LTAC was associated with no difference in survival and lower costs. These results underscore the importance of addressing unmeasured confounding and selection in cases when treatment assignment is chosen by physicians. Given that LTACs entirely select their patients for admission, it is not surprising that selection bias was so large. The fact that our instrumental variable analyses were specified a priori helps support the validity of these findings. That being said, instrumental variable analyses do require assumptions that cannot be proven, and these results should be interpreted accordingly.
Our study has several limitations. First, we studied only patients with chronic critical illness, which represent only a portion of the patients eligible for transfer to LTACs. Patients with lower acuity and fewer care needs may not experience similar outcomes. Second, although we used a validated administrative definition of chronic critical illness, the performance characteristics of our definition may vary among patient groups. In particular, our definition would exclude patients transferred to LTACs very early in their hospital course. Our approach represents a balance between including the most eligible patients and restricting the analysis to patients most likely to benefit. Third, our study examined only 1 type of specialized care for chronic critical illness-we could not examine the role of step-down units or intermediate care units within acute care hospitals. Fourth, we employed a macro-costing method, that, while internally valid, may overstate cost differences when a large proportion of costs are variable, such as nursing costs. This issue may limit inference as to cost differences between LTAC and non-LTAC patients, as nursing costs are subsumed in the daily bed charges for each patient. Unfortunately, more granular methods of measuring costs are not available in MedPAR. Nor are home health or outpatient costs available in MedPAR, although these costs are likely small compared with inpatient costs. Finally, we used an instrumental variable approach to address selection and unmeasured confounding.
Although we undertook extensive steps to identify a valid instrument, our results could be sensitive to instrument choice, and are only applicable to the marginal patient, that is a patient with a definable probability of being either transferred or not transferred to an LTAC. 32 In identifying a subset of patients for which LTAC care is equally effective and potentially less costly, we demonstrate how the tools of comparative effectiveness research can be used to examine the role of novel health delivery approaches in our health care system.
CONCLUSIONS
In identifying a subset of patients for which LTAC care is equally effective and potentially less costly, we demonstrate how the tools of comparative effectiveness research can be used to examine the role of novel health delivery approaches in our health care system. LTACs are a prime example of how financial incentives can radically change health care delivery. The expansion of the LTAC model was driven by payment structures that create incentives for early hospital discharge for severely ill patients, rather than clear evidence of clinical or financial benefit. 10 Nonetheless, it is possible to critically examine these changes in ways that can inform policy decisions. Policy makers can use these results to reevaluate payment models for LTACs in ways that result in costs savings from the societal and payer perspectives, while at the same time improving the quality of care for hospitalized patients. Bundled payments, use of accountable care organizations, and other financial incentives to optimize LTAC utilization have the potential to better integrate episodes of acute care while maximizing value of LTACs to the health system.
